Bone marrow stem cell protection from chemotherapy by low-molecular-weight compounds

Experimental Hematology

Volumn 29, Issue 2, 2001, Pages 123-137

  Guest, Ian ^a   Uetrecht, Jack ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anticancer drugs; Bone marrow; Hematopoietic stem cell

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ACETYL SERINE ASPARTIC ACID LYSINEPROLINE; AMIFOSTINE; AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME C OXIDASE; CYTOKINE; DITHIOCARBAMIC ACID DERIVATIVE; GLUTAMIC ACID GLUTAMIC ACID ASPARTIC ACID CYSTEINE LYSINE; GLUTATHIONE; GROWTH FACTOR; MAFOSFAMIDE; MOFAROTENE; PEPTIDE; THYMOSIN BETA4; UNCLASSIFIED DRUG;

BLOOD TOXICITY; BONE MARROW CELL; CELL CYCLE; CELL FUNCTION; CELL PROTECTION; COLONY FORMATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

AMIFOSTINE; ANEMIA, APLASTIC; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; ETHYLENES; GROWTH INHIBITORS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKOPENIA; MEDLINE; MOLECULAR WEIGHT; OLIGOPEPTIDES; PYRROLIDONECARBOXYLIC ACID; THROMBOCYTOPENIA;

EID: 0035144028     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(00)00621-4     Document Type: Review

References (203)

1. The hemopoietic system; structure and regulation
2. Purification and characterization of mouse hematopoietic stem cells
3. + murine hematopoietic cells
4. Long-term lymphopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell
5. + cells
6. A novel five-transmembrane hematopoietic stem cell antigen; isolation, characterization and molecular cloning
7. + cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors
8. A newly discovered class of human hematopoietic cells with SCID-repopulating activity
9. - hematopoietic stem cells using cell surface markers AC133 and CD7
10. Hemopoietic spleen colony studies
11. Regulation of hemopoiesis by bone marrow stromal cells and their products
12. Interactions of hematopoietic progenitor cells with extracellular matrix
13. Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation
14. Compartmentalization of a haematopoietic growth factor (GM-CSF) by glycosaminoglycans in the bone marrow microenvironment
15. Heparan sulphate bound growth factors; a mechanism for stromal cell mediated hemopoiesis
16. Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates; requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins
17. Fibronectin and VLA-4 in hematopoietic stem cell-microenvironment interactions
18. Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin
19. hi stem cells to bone marrow stroma
20. α4 integrins regulate the proliferation/differentiation balance of multilineage hematopoietic progenitors in vivo
21. The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by human hematopoietic progenitors and bone marrow stromal cells that serves as a potent negative regulator of hematopoiesis
22. Stromal cell CD9 and the differentiation of hematopoietic stem/progenitor cells
23. A soluble form of human delta-like-1 inhibits differentiation of hematopoietic progenitor cells
24. The growth inhibitory role and potential clinical value of macrophage inflammatory protein 1-α in myeloid leukemias
25. Some hemopoietic negative regulators
26. Functional heterogeneity is associated with the cell cycle status of murine hematopoietic stem cells
27. Differentiation and proliferation of hematopoietic stem cells
28. 0
29. 0
30. The membrane-bound isoform of stem cell factor synergizes with soluble flt3 ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic anemia bone marrow
31. Defining optimum conditions for the ex vivo expansion of human umbilical cord blood cells. Influences of progenitor enrichment, interference with feeder layers, early-acting cytokines and agitation of culture vessels
32. Intrinsic potential of phenotypically defined human hemopoeitic stem cells to self-renew in short-term in vitro cultures
33. Long-term marrow culture; an overview of techniques and experience
34. The SCID-hu mouse; murine model for the analysis of human hematolymphoid differentiation and function
35. Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice
36. A direct measurement of the radiation sensitivity of normal mouse bone marrow
37. DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients
38. An inhibitor of stem cell proliferation in normal bone marrow
39. Inhibition of CFU entry into cycle by a bone marrow extract
40. Isolation and synthesis of a hemoregulatory peptide
41. Type β transforming growth factor; a bifunctional regulator of cellular growth
42. Effects of recombinant tumor necrosis factor on proliferation and differentiation of leukemic and normal hemopoietic cells in vitro
43. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia; synergism of tumor necrosis factor and interferon-γ
44. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-β
45. Synergy of interleukin-1 and granulocyte colony-stimulating factor; in vitro stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice
46. Protective effects of IL-1 on human hematopoietic progenitor cells treated in vitro with 4-hydroperoxycyclophosphamide
47. The effects of tumor necrosis factor-α on early human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide
48. Suppressor cytokines and regulation of myelopoiesis. Biology and possible clinical uses
49. Human chemokines; enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice
50. Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities
51. Hematopoietic growth factors in cancer treatment
52. Hematopoietic cell proliferation and hematopoietic growth factors
53. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity
54. Haemoprotection against cytostatic drugs by stem cell inhibition
55. Bone marrow protection
56. Inhibitory peptides in hematopoiesis
57. A review of the use of chemoprotectants in cancer chemotherapy
58. Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer
59. Chemoprotectants; a review of their clinical pharmacology and therapeutic efficacy
60. Experience with syngeneic marrow transplantation in Brown-Norway and Wistar-Furth rat models of acute myelogenous leukemia
61. Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide
62. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines
63. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L 1210 leukemia
64. Ex vivo manipulation of hematopoietic stem cells for transplantation; the potential role of amifostine
65. Inhibitory effects of a synthetic pentapeptide on hematopoietic stem cells in vitro and in vivo
66. Prevention of hematotoxic side effects of cytostatic drugs by a synthetic hemoregulatory peptide
67. The use of haemoregulatory peptides (pEEDCK monomer and dimer) for reduction of cytostatic drug induced haemopoietic damage
68. The hematoregulatory peptide pEEDCK may inhibit stem cell proliferation via hydropathic binding to antisense sequence motifs in interleukin-11 and other growth factors
69. Effects of CFU-S inhibitors on murine bone marrow during ARA-C treatment-I. Effects on stem cells
70. + subpopulations in response to growth factors
71. Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP.I. The precise point of the cell cycle sensitive to AcSDKP. Studies on the effect of AcSDKP on GM-CFC and on the possible involvement of T-lymphocytes in AcSDKP response
72. The mechanism of action of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in the control of haematopoietic stem cell proliferation
73. Enhancement of the adherence of hematopoietic stem cells to mouse bone marrow-derived stromal cell line MS-1-T by a tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro
74. Biological activities of tetrapeptide AcSDKP on hematopoietic cell binding to the stromal cell in vitro
75. 4 synergizes with human granulocyte-macrophage colony-stimulating factor in maintaining bone marrow proliferation
76. 4, inhibitor for normal hematopoietic progenitor cells
77. Effects of a hematoregulatory peptide (HP5b) on erythroid and myelopoietic colony formation in vitro
78. Effects of small peptidic inhibitors of murine stem cells on human normal and malignant cells
79. Suppressive biological activity of a synthetic pentapeptide on highly enriched human and murine marrow hematopoietic progenitors; synergism with recombinant human tumor necrosis factor-α and interferon-γ
80. Inhibition of hematopoietic stem cell proliferation by hemoregulatory peptide PyroGlu-Glu-Asp-Cys-Lys (pEEDCK) provides protection against short-term neutropenia and long-term damage
81. Pre-CFU-S quiescence and stem cell exhaustion after cytostatic drug treatment; protective effects of the inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK)
82. The dimer of hematoregulatory peptide (HP5b) stimulates mouse and human myelopoiesis in vitro
83. Regulation of colony-stimulating activity production from bone marrow stromal cells by the hematoregulatory peptide, HP-5
84. Indirect stimulation of hemopoiesis by hemoregulatory peptide (HP5b) dimer in murine long-term bone marrow cultures
85. 2; a single-factor alternative for multifactor cocktails
86. Protection from arabinofuranosylcytosine and n-mustard-induced myelotoxicity using hemoregulatory peptide pGlu-Glu-Asp-Cys-Lys monomer and dimer
87. Activated granulocytes oxidize the endogenous stem cell inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK) to the stimulatory dimer; a redox-mediated mechanism for demand-induced hematopoietic regulation
88. Glutathione; an in vitro granulopoiesis inhibitor at nanomolar concentration, isolated from calf spleen
89. + hematopoiesis
90. Protection of mice against lethal doses of 1β-D-arabinofuranosylcytosine by pluripotent stem cell inhibitors
91. Inhibitor of hematopoietic pluripotent stem cell proliferation; purification and determination of its structure
92. AcSDKP, an inhibitor of CFU-S proliferation, is synthesized in mice under steady-state conditions and secreted by bone marrow in long-term culture
93. 1-S transition of rat hepatocytes
94. Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP
95. In vivo modifications of AcSDKP metabolism and haematopoiesis in mice treated with 5-fluorouracil and Goralatide
96. The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity; improvements in mice survival and protection of bone marrow stem cells and progenitors
97. Goralatide (AcSDKP), a negative growth regulator, protects the stem cell compartment during chemotherapy, enhancing the myelopoietic response to GM-CSF
98. Circadian-based effects of AcSDKP, with or without rhG-CSF on hematological toxicity of chemotherapy in mice
99. Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation
100. The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture; evidence for an indirect mechanism
101. Reversible inhibitory effects and absence of toxicity of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in human long-term bone marrow culture
102. The tetrapeptide AcSDKP, a physiological inhibitor of normal cell proliferation, reduces the S phase entry of continuous cell lines
103. Comparison of the effects of AcSDKP, thymosin β4, macrophage inflammatory protein 1α and transforming growth factor β on human leukemic cells
104. The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654)
105. Enhanced engraftment of intravenously transplanted hematopoietic stem cells into bone marrow of irradiated mice treated with AcSDKP
106. Production and consumption of the tetrapeptide AcSDKP, a negative regulator of hematopoietic stem cells, by hematopoietic microenvironmental cells
107. Involvement of human plasma angiotensin 1-converting enzyme in the degradation of the haematoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline
108. The hematoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme
109. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-Acetyl-Seryl-Aspartyl-Lysyl-Proline
110. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline; a new marker of chronic angiotensin-converting enzyme inhibition
111. 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro, a regulator of the hematopoietic system
112. Phase I-II trial of Seraspenide, a suppressor of myelopoiesis, protects against cytarabine and ifosfamide monochemotherapy myelotoxicity
113. Purging of breast cancer cells from bone marrow using WR-2721 and 4-hydroperoxycyclophosphamide
114. In vitro effect of amifostine on hematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs; haematoprotection acts as a drug-specific progenitor rescue
115. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukemic effects
116. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity
117. Cell cycle redistribution of cultured cells after treatment with chemical radiation protectors
118. Inhibition of topoisomerase IIα activity in CHO K1 cells by 2-[(aminopropyl)amino]ethanethiol (WR-1065)
119. Commitment to erythroid differentiation in mouse erythroleukemia cells is controlled by alterations in topoisomerase IIα phosphorylation
120. 1 and downregulates cell cycle progression through a p53-dependent pathway
121. Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-kB/Rel transcription factors
122. Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-O-O′)tellurate (AS101)
123. Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101
124. Radioprotective effects of the immunomodulator AS101
125. The immunomodulator AS-101 inhibits IL-10 release and augments TNFα and IL-1α release by mouse and human mononuclear phagocytes
126. Synergistic anti-tumoral effect of paclitaxel (taxol) + AS101 in a murine model of B16 melanoma; association with ras-dependent signal-transduction pathways
127. Mechanism of diethyldithiocarbamate modulation of murine bone marrow toxicity
128. IL-1β mediates diethyldithiocarbamate-induced granulocyte colony-stimulating factor production and hematopoiesis
129. The anti-tumor arotinoid Ro 40-8757 protects bone marrow from the toxic effects of 5-fluorouracil
130. Mofarotene (Ro 40-8757) inhibits hematopoiesis in vitro by preventing maturation from primitive progenitor cells
131. Down-regulation of mitochondrial gene expression by the anti-tumor arotinoid mofarotene (Ro 40-8757)
132. Arotinoid mofarotene (Ro 40-8757) up-regulates p21 and p27 during growth inhibition of pancreatic cancer cell lines
133. The incidence of secondary leukemias
134. Hematopoietic stem cell quiescence maintained by p21
135. Inhibition of DNA synthesis in murine bone-marrow cells by AET and cysteamine
136. Bioavailability and newer methods of delivery of phosphorothioate radioprotectors
137. Differential chemoprotection of normal and malignant tissues
138. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine
139. Active vs passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)ethylphosphorothioic acid
140. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects
141. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine
142. A risk-benefit assessment of amifostine in cytoprotection
143. Interaction of cultured mammalian cells with WR-2721 and its thiol, WR-1065; implications for mechanisms of radioprotection
144. Radioprotection of cells in culture by WR-2721 and derivatives; form of the drug responsible for protection
145. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents; a molecular approach
146. Amifostine improves the antileukemic therapeutic index of mafosfamide; implications for bone marrow purging
147. Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard; amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery
148. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors
149. WR-2721 protects against the hematological toxicity of cyclophosphamide; a controlled phase II trial
150. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy
151. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities; results of a randomized control trial in patients with advanced ovarian cancer
152. Amifostine (WR2721) for dose escalation in marrow-ablative treatment of leukemia
153. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support
154. Use of amifostine in bone marrow purging
155. Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin-4
156. Mechanism of action of aminothiol radioprotectors
157. Conformational changes in chromatin structure induced by the radioprotective aminothiol, WR 1065
158. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro and in comparison to the effects of thiosulphate and diethyldithiocarbamate
159. A new immunomodulating compound (AS-101) with potential therapeutic application
160. The biological activity and immunotherapeutic properties of AS-101, a synthetic organotellurium compound
161. Protective and restorative role of AS101 in combination with chemotherapy
162. Use and mechanism of action of AS101 in protecting bone marrow colony forming units-granulocyte-macrophage following purging with ASTA-Z 7557
163. The protective role of ammonium trichloro(dioxoethylene-O, O′)tellurate in combination with several cytotoxic drugs acting by different mechanisms of action
164. Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice
165. Immunological effects of AS101 in the treatment of cancer patients
166. Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide
167. Synergism between AS101 and PMA in lymphokine production
168. Calcium and ionophore A-23187 as initiators of DNA replication in the pluripotent haemopoietic stem cell
169. In vivo synergistic effect of the immunomodulator AS101 and the PKC inducer bryostatin
170. Effect of AS101 on bryostatin 1-mediated differentiation induction, cell cycle arrest, and modulation of drug-induced apoptosis in human myeloid leukemia cells
171. The protective action of dithiocarbamates against the lethal effects of x-irradiation in mice
172. Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model
173. Effect of diethyldithiocarbamate rescue on tumor response to cis-platinum in a rat model
174. Evaluation of the immunomodulatory potential of diethyl dithiocarbamate derivatives
175. Modification of the bone marrow toxicity of cis-diamminedichloroplatinum(II) in mice by diethyldithiocarbamate
176. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut and bone marrow by diethyldithiocarbamate
177. Diethyldithiocarbamate inhibition of murine bone marrow toxicity caused by cis-diamminedichloroplatinum (II) or diammine-(1,1-cyclobutanedicarboxylato)-platinum (II)
178. Myeloprotective effect of diethyldithiocarbamate treatment following 1,3-Bis(2-chloroethyl)-1-nitrosourea, adriamycin or mitomycin C in mice
179. Effect of diethyldithiocarbamate on toxicity of doxorubicin, cyclophosphamide and cis-diamminedichloroplatinum (II) on mice haemopoietic progenitor cells
180. Diethyldithiocarbamate modulation of murine bone marrow toxicity induced by cis-diammine(cyclobutanedicarboxylato)platinum(II)
181. Diethyldithiocarbamate induction of cytokine release in human long-term bone marrow cultures
182. High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer
183. Diethyldithiocarbamate chemoprotection of carboplatin-induced hematological toxicity
184. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
185. - immunodeficient patients
186. -SCID; initial trial results after 4 years
187. Progress in adeno-associated virus type 2 vector production; promises and prospects for clinical use
188. + cells via human immunodeficiency virus-based gene transfer vectors
189. + cells using particle-mediated gene delivery
190. Suppression of TNF-α-induced apoptosis by NF-κB
191. Engraftment of hematopoietic progenitor cells transduced with Fanconi anemia group C gene (FANCC)
192. Bone marrow stromal cell-mediated gene therapy for hemophilia A; in vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648
193. + cells from patients with Gaucher disease; in vivo detection of transduced cells without myeloablation
194. Regulated production of mature insulin by non-β-cells
195. Multipotential marrow stromal cells transduced to produce L-DOPA; engraftment in a rat model of Parkinson disease
196. Latest developments in gene transfer technology; achievements, perspectives and controversies over therapeutic applications
197. + cells
198. Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoietic progenitor cells
199. + cells to protect them against alkylating agents
200. Engraftment of MDR1 and neoR gene-transduced hematopoietic cells after breast cancer chemotherapy
201. Retroviral transduction of enriched hematopoietic stem cells allows lifelong bcl-2 expression in multiple lineages but does not perturb hematopoiesis
202. + cells